Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives

Projected revenue gains depend in part on higher rates from legacy payer contracts still being renegotiated.

Rhea-AI Summary

Vivos Therapeutics (VVOS) has begun restructuring to target $3.6 million in annual overhead savings starting in Q4 2026. Some measures are in place, with further cuts effective October 1; Vivos expects the full reductions during Q4.

Referrals to its Las Vegas centers rose approximately threefold from the first of June through September 27. Related revenue is expected from Q4 into 2027. Vivos projects a $1.5 million to $3.0 million annualized revenue run rate for its EEG testing and treatment initiative in Q4, up from near zero in May. Its remote patient monitoring program is expected to add annualized revenue of up to $3.5 million by Q1 2027. Vivos expects legacy payer contract rate increases to add $2.4 million to $5.6 million in revenue, with full realization expected in early 2027 and over the next six to nine months. Management targets positive cash flow by late 2026 or early 2027 and profitability in 2027.

9 points · 4 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Restructuring targets estimated annual overhead savings of $3.6 million beginning in Q4 2026.
• Major point. Forward-looking: it has not happened yet and may not happen.Vivos projects a $1.5 million to $3.0 million annualized EEG initiative revenue run rate in Q4, up from near zero in May.
• Major point. Forward-looking: it has not happened yet and may not happen.Vivos expects remote patient monitoring to add annualized revenue of up to $3.5 million by Q1 2027.
• Major point. Forward-looking: it has not happened yet and may not happen.Vivos expects legacy payer rate increases to add $2.4 million to $5.6 million in revenue with very little associated cost.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Management targets positive cash flow by late 2026 or early 2027.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Management targets profitability in 2027.

3 minor points

• Minor point. Forward-looking: it has not happened yet and may not happen.Some cost reductions are already implemented; Vivos expects the full cuts in Q4 2026.
• Minor pointLas Vegas center referrals rose approximately threefold from the first of June through September 27.
• Minor point. Forward-looking: it has not happened yet and may not happen.Vivos expects referral-related revenue to appear from Q4 2026 into 2027.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Staff reductions are a primary source of the planned overhead savings.
• Minor pointLegacy payer contracts are still being renegotiated; full fee increases are expected in early 2027 and over the next six to nine months.

News Explained

As a liquidity baseline for the announced cost and revenue plans, Vivos reported $1.774 million in cash and equivalents at June 30, 2026, equal to 51.3 days of second-quarter operating cash use at that quarter’s rate.

Sources and calculations

• Vivos Therapeutics cost reduction and revenue initiatives release (2026-09-29)
• Vivos Therapeutics Q2 2026 fundamentals (2026Q2)

• Available liquidity against the last reported quarterly operating outflow, in days at that rate $1,774,000 / ($3,148,000 / 91) = 51.3 days

Argus 15 min delay 56 alerts

+2.61% vs previous close $0.14 last price 366.1x rel. volume Open Argus

Details

Market Reaction – VVOS

$0.13 – $0.20 Day Range

$2.77M Market Cap

On Sep 29, the day this news came out, the latest delayed price for VVOS is 2.61% above the previous close. Our momentum scanner has recorded 56 alerts for this stock so far that day. The latest delayed price is $0.14. Relative volume is exceptionally heavy at 366.1x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

On Aug 14, Vivos reported $5.2M of quarterly revenue and a $13.2M first-half net loss, giving the cu...

Analysis

On Aug 14, Vivos reported $5.2M of quarterly revenue and a $13.2M first-half net loss, giving the current cost-reduction and revenue-growth plans reported financial context.

Key Figures

Estimated annual savings: $3.6 million annually Las Vegas referral growth: Approximately 3-fold EEG testing and treatment run rate: $1.5–$3.0 million annualized +3 more

Estimated annual savings

$3.6 million annually

Cost-reduction plan beginning in Q4 2026

Las Vegas referral growth

Approximately 3-fold

From June 1 through September 27

EEG testing and treatment run rate

$1.5–$3.0 million annualized

Projected for Q4 2026

Remote patient monitoring revenue

Up to $3.5 million annualized

Expected by Q1 2027

Payer contract revenue impact

$2.4–$5.6 million

Expected from legacy payer contract fee increases

Cash flow and profitability objectives

Cash flow positive by late 2026 or early 2027; profitable in 2027

Management's stated objectives

Historical Context

1 past event · Latest: Aug 25

1 event

1. Aug 25

   Referral growth

   24h Move

   -5.8%

   Nevada referrals rose 212% over six weeks and nearly five-fold since June 1.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

obstructive sleep apnea, eeg, remote patient monitoring, 510(k)

4 terms

obstructive sleep apnea medical

"methods for patients with obstructive sleep apnea"

Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.

eeg medical

"The Company’s EEG diagnostic testing and treatment initiative"

An EEG (electroencephalogram) is a medical test that records the brain’s electrical activity through small sensors placed on the scalp, similar to reading patterns of a city’s traffic to understand flow and disruptions. For investors, EEGs matter because they are central to diagnosing and monitoring neurological conditions, validating new brain-related treatments or devices, and supporting regulatory approvals and reimbursement — factors that drive market demand and revenue potential. Changes in EEG technology, usage or guidelines can affect companies that make the equipment, offer related services, or develop therapies tied to brain signals.

remote patient monitoring medical

"executing on a Remote Patient Monitoring (RPM) program"

Remote patient monitoring is the ongoing collection and transmission of a person’s health data (such as heart rate, blood sugar, or blood pressure) from home or another non-clinical setting to healthcare providers using connected devices and secure networks. For investors, it matters because it can reduce hospital visits, create steady service and device revenue, and change how care is paid for—think of it as a home security system for health that can lower costs and improve outcomes.

510(k) regulatory

"the only FDA 510(k) cleared technology"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue

LITTLETON, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other breathing and sleep disorders, today announced execution by management on a restructuring and cost reduction plan aimed at saving an estimated $3.6 million annually, beginning in Q4 2026. Parts of the plan have already been implemented, with additional reductions going into effect October 1, 2026. The primary savings in the plan come from staff reductions, vendor relationship changes, negotiated contract savings, and more. The Company expects the full measure of cuts to take place in the fourth quarter of 2026.

In addition to the announced expense reductions, management has also pursued a number of revenue growth initiatives that are beginning to deliver meaningful financial returns. Consistent with the Company’s previously announced growth, referrals into the Company’s Las Vegas Sleep and Airway Medicine Centers continued to rise approximately 3-fold from the first of June through September 27. Revenue from the recent surge in referrals is expected to begin showing up in the fourth quarter and into 2027.

Additional revenue is expected from the Company’s EEG diagnostic testing and treatment initiative, which has also grown from near zero in May to a projected annualized run rate of between $1.5 and $3.0 million in the fourth quarter. The Company is also executing on a Remote Patient Monitoring (RPM) program that is expected to add to top line revenue at an annualized rate of up to $3.5 million by the first quarter of 2027.

Vivos management is also actively engaged in renegotiating legacy payer contracts to bring them up to market rates. The expected range of revenue impact is between $2.4 million and $5.6 million, with very little associated costs. The full realization of these fee increase are expected in early 2027 and throughout the next six to nine months.

R. Kirk Huntsman, Vivos' Chairman and Chief Executive Officer, stated, "Our management team is laser focused on all of our restructuring and revenue growth initiatives. Perhaps the most compelling is our ongoing conversions and replacement of legacy IT and software systems and infrastructure that dramatically leverage AI and allow us significant and material labor savings.”

When all of these operational expense reductions and revenue growth initiatives are factored in, Vivos management believes the Company will be on track to meet its stated objective of being cash flow positive by late 2026 or early 2027 and profitable in 2027.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the flagship DNA appliance is the first to receive clearance for treating moderate to severe OSA in children.

OSA affects an estimated one billion adults aged 30-69 years old worldwide, yet 80% or more remain undiagnosed and unaware of their condition. These chronic disorders are not just a sleep issue—they are closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes. Vivos CARE oral medical devices are designed to help address anatomical factors often associated with OSA.

Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly..

A 2019 analysis published in The Lancet Respiratory Medicine estimated that approximately 936 million adults aged 30 to 69 worldwide have OSA. Through technology, education, provider partnerships and acquisitions, Vivos seeks to expand access to more comprehensive and personalized OSA diagnosis and treatment.

Vivos calls the use of its appliances and related clinical protocols to treat OSA The Vivos Method, a proprietary, clinically effective solution that is a nonsurgical, noninvasive, and nonpharmaceutical approach designed to address the complex needs of OSA patients, and which provides hope to allow patients to Breathe New Life.

For more information, visit www.vivos.com.

Cautionary Note Regarding Forward-Looking Statements

This press release, including statements of the Company's management and other parties made in connection therewith, contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning future events. Words such as "may," "would," "should," "expects," "projects," "potential," "intends," "plans," "believes,", “hopes”, "anticipates," "estimates," "goal," "aim," and variations of such words and similar expressions are intended to identify forward-looking statements.

Forward-looking statements in this press release include, without limitation, statements regarding the anticipated future impact on the Company's the estimated annual expense savings from the Company's cost reduction initiatives, including the assumption that such savings will approximate $3.6 million on an annualized basis; the Company's expectations regarding patient demand and medical referrals; and the Company's goal of becoming cash flow positive.

These statements involve significant known and unknown risks and are based on assumptions and estimates subject to uncertainties and contingencies, many of which are beyond Vivos' control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to effectively market or sell products or continue to integrate business from the acquisition and alliance model into its own or otherwise implement sales, marketing, and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (iv) the risk that Vivos may be unable to secure additional financing to continue operations, acquire additional sleep centers practices or enter into management services support affiliations on reasonable terms, or maintain its Nasdaq listing when needed, if at all, (v) the risk that actual cost savings from cost reduction initiatives may be less than estimated or may be offset by transition costs, severance obligations, or operational disruptions, (vi) the risk that restructuring and revenue growth initiatives and reimbursement rate changes may not be as significant as expected, (vii) the risk that patient volume increases may not materialize at the pace or magnitude anticipated, (viii) market and other conditions that could impact Vivos’ business or ability to obtain financing; and (ix) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (the "SEC"), which are available free of charge at www.sec.gov.

Except as required by applicable law, Vivos undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.

Vivos Investor Relations Contact:

Jennifer Hauser, Executive Assistant to the CEO
jhauser@vivoslife.com
720-927-3125

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How does Vivos Therapeutics plan to achieve its overhead savings?

Vivos identifies staff reductions, changes to vendor relationships and negotiated contract savings as primary sources. Management also expects its ongoing replacement of legacy IT and software systems, using AI, to reduce labor costs.